Assignee
SIGNAL PHARM LLC
US·103 granted patents·25 pending applications·952 citations·filing 1998–2024
Top patents by PatentIndex Score
128 records- 0198US7981893B2Heteroaryl compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2007·Granted Jul 19, 2011·90 cites·10 claims
- 0297US9512124B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2015·Granted Dec 6, 2016·32 cites·60 claims
- 0397US9365524B2Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their useSIGNAL PHARM LLC·Filed 2015·Granted Jun 14, 2016·22 cites·36 claims
- 0496US9814713B2Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their useSIGNAL PHARM LLC·Filed 2016·Granted Nov 14, 2017·14 cites·21 claims
- 0596US9737541B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2016·Granted Aug 22, 2017·12 cites·52 claims
- 0696US9701643B2Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2015·Granted Jul 11, 2017·19 cites·18 claims
- 0795US8383634B2Methods of treatment using heteroaryl compounds and compositions thereofSIGNAL PHARM LLC·Filed 2011·Granted Feb 26, 2013·46 cites·4 claims
- 0895US8372976B2Methods of treatment comprising the administration of heteroaryl compoundsSIGNAL PHARM LLC·Filed 2011·Granted Feb 12, 2013·40 cites·1 claims
- 0995US7968556B2Heteroaryl compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2007·Granted Jun 28, 2011·41 cites·3 claims
- 1095US7723340B2Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2006·Granted May 25, 2010·46 cites·51 claims
- 1194US10040770B2Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2017·Granted Aug 7, 2018·7 cites·18 claims
- 1294US7521446B2Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2006·Granted Apr 21, 2009·39 cites·60 claims
- 1393US10266500B2Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2018·Granted Apr 23, 2019·5 cites·14 claims
- 1493US9187479B2Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2014·Granted Nov 17, 2015·17 cites·12 claims
- 1593US7759342B2Methods of treatment and prevention using haloaryl substituted aminopurinesSIGNAL PHARM LLC·Filed 2007·Granted Jul 20, 2010·35 cites·7 claims
- 1693US7129242B2Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related theretoSIGNAL PHARM LLC·Filed 2001·Granted Oct 31, 2006·59 cites·2 claims
- 1792US11325890B2Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2020·Granted May 10, 2022·2 cites·18 claims
- 1892US9725450B2Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2015·Granted Aug 8, 2017·9 cites·9 claims
- 1992US9493466B2Treatment of cancer with TOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2012·Granted Nov 15, 2016·7 cites·5 claims
- 2092US9359364B2Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b] pyrazin-2(1H)-oneSIGNAL PHARM LLC·Filed 2014·Granted Jun 7, 2016·10 cites·28 claims
- 2191US9796685B2Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-Methylcyclohexylamino)-pyrimidine-5-carboxamideSIGNAL PHARM LLC·Filed 2015·Granted Oct 24, 2017·14 cites·7 claims
- 2290US10004735B2Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazinesSIGNAL PHARM LLC·Filed 2017·Granted Jun 26, 2018·4 cites·16 claims
- 2390US9737535B2Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazinesSIGNAL PHARM LLC·Filed 2015·Granted Aug 22, 2017·5 cites·16 claims
- 2490US9474757B2Methods for treating cancer using TOR kinase inhibitor combination therapySIGNAL PHARM LLC·Filed 2014·Granted Oct 25, 2016·16 cites·20 claims
- 2590US9155736B2Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activitySIGNAL PHARM LLC·Filed 2013·Granted Oct 13, 2015·16 cites·6 claims
- 2689US9556126B2Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2014·Granted Jan 31, 2017·10 cites·32 claims
- 2789US9505764B2Treatment of cancer with dihydropyrazino-pyrazinesSIGNAL PHARM LLC·Filed 2014·Granted Nov 29, 2016·11 cites·33 claims
- 2889US9358232B2Methods for treating cancer using TOR kinase inhibitor combination therapySIGNAL PHARM LLC·Filed 2014·Granted Jun 7, 2016·13 cites·6 claims
- 2988US10398700B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2018·Granted Sep 3, 2019·2 cites·11 claims
- 3088US9771371B2Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2015·Granted Sep 26, 2017·4 cites·6 claims
- 3188US9513297B2Methods for measurement of inhibition of c-Jun N-terminal kinase in skinSIGNAL PHARM LLC·Filed 2015·Granted Dec 6, 2016·14 cites·6 claims
- 3288US9403829B2Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1H)-one, a solid form thereof and methods of their useSIGNAL PHARM LLC·Filed 2012·Granted Aug 2, 2016·13 cites·29 claims
- 3388US9375443B2Method for treating advanced non-small cell lung cancer (NSCLC) by administering a combination of a TOR kinase inhibitor and azacitidine or erlotinibSIGNAL PHARM LLC·Filed 2013·Granted Jun 28, 2016·12 cites·4 claims
- 3488US9198866B2Pharmaceutical formulations of a substituted diaminopurineSIGNAL PHARM LLC·Filed 2013·Granted Dec 1, 2015·15 cites·18 claims
- 3588US7354947B2Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof a JNK inhibitors and compositions and methods related theretoSIGNAL PHARM LLC·Filed 2005·Granted Apr 8, 2008·10 cites·4 claims
- 3688US2025000860A1Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their useSIGNAL PHARM LLC·Filed 2024·Application pending·0 cites
- 3787US10149849B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2017·Granted Dec 11, 2018·2 cites·3 claims
- 3886US10919865B2Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2019·Granted Feb 16, 2021·3 cites·16 claims
- 3986US9156798B2Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2015·Granted Oct 13, 2015·5 cites·30 claims
- 4086US7442699B2Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related theretoSIGNAL PHARM LLC·Filed 2005·Granted Oct 28, 2008·10 cites·8 claims
- 4186US7220771B2Methods of using indazole derivatives as JNK inhibitorsSIGNAL PHARM LLC·Filed 2003·Granted May 22, 2007·22 cites·4 claims
- 4285US10975039B2Isotopologues of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamideSIGNAL PHARM LLC·Filed 2020·Granted Apr 13, 2021·1 cites·7 claims
- 4385US10940152B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2020·Granted Mar 9, 2021·1 cites·27 claims
- 4485US8686135B2Methods of synthesis and purification of heteroaryl compoundsSIGNAL PHARM LLC·Filed 2013·Granted Apr 1, 2014·8 cites·21 claims
- 4585US6987184B2Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof as JNK inhibitors and compositions and methods relatedSIGNAL PHARM LLC·Filed 2002·Granted Jan 17, 2006·19 cites·4 claims
- 4684US10689351B2Isotopologues of 2-(tert butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamideSIGNAL PHARM LLC·Filed 2019·Granted Jun 23, 2020·1 cites·7 claims
- 4784US10646493B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2019·Granted May 12, 2020·1 cites·20 claims
- 4884US10131639B2Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4methylcyclohexylamino)-pyrimidine-5-carboxamideSIGNAL PHARM LLC·Filed 2017·Granted Nov 20, 2018·4 cites·18 claims
- 4984US9079900B2Methods of synthesis and purification of heteroaryl compoundsSIGNAL PHARM LLC·Filed 2014·Granted Jul 14, 2015·5 cites·27 claims
- 5084US8907087B2Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2013·Granted Dec 9, 2014·4 cites·11 claims
Showing the top 50 of 128 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →